德泽佩卢马布可以恢复严重,不受控制的喘患者的正常肺功能:PATHWAY和NAVIGATOR研究的综合结果
Ian D Pavord1, Christopher E Brightling2, Stephanie Korn3
1Respiratory Medicine, National Institute for Health and Care Research Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK. ian.pavord@ndm.ox.ac.uk.
Pulmonary therapy
|April 26, 2025
概括
与安慰剂相比,Tezepelumab治疗有助于更多患有严重喘和肺功能异常的患者实现正常的肺功能. 这种喘疗法在恢复肺功能方面显著改善.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 严重的,不受控制的喘通常与异常的肺功能有关.
- 恢复正常的肺功能是喘患者的关键治疗目标.
- 以前的研究表明,tzepelumab在减少喘恶化方面具有有效性.
研究的目的:
- 评估tzepelumab在严重喘患者中恢复正常肺功能的能力.
- 分析基于基线肺功能和生物标志物的肺功能恢复.
- 为了评估来自PATHWAY和NAVIGATOR试验的患者的治疗效果.
主要方法:
- 来自两个随机,双盲,安慰剂控制的研究 (PATHWAY和NAVIGATOR) 的汇总数据的后期分析.
- 患者每4周服用210毫克tezepelumab或安慰剂进行皮下注射,持续52周.
- 分析的重点是患者异常的前支气管扩展剂 (BD) 强迫呼吸量在1秒 (FEV1) <80%在基线.
主要成果:
- 在患有异常起始肺功能的患者中,Tezepelumab 改善了0.14 L 的前BD FEV1 与安慰剂相比.
- 与安慰剂 (9.9%) 相比,在第52周,接受tzepelumab的患者中 (17.2%) 的比例更高,实现了正常的肺功能.
- 较高的2型炎症生物标志物和较短的疾病持续时间与tezepelumab的更好的肺功能恢复相关.
结论:
- 采佩卢马布治疗导致更大比例的患有严重喘和异常出血期肺功能的患者实现了正常的肺功能.
- 这项研究强调了tezepelumab在重症喘患者特定亚组的肺功能恢复方面的潜力.
- 这些研究结果支持特塞佩卢马布作为一种治疗严重喘的治疗选择,旨在改善肺功能结果.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
156
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
156
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
COPD: Management Using Bronchodilators and Corticosteroids
122
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
122
Asthma-III: Symptoms and Complications
2.4K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.4K
Asthma: Pathogenesis and Management
231
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
231
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K


